Page last updated: 2024-12-11

cra1000

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

CRA1000: a non-peptidic corticotropin-releasing hormone receptor type 1 antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9849313
CHEMBL ID297986
SCHEMBL ID6171730
MeSH IDM0301385

Synonyms (17)

Synonym
PDSP2_001710
PDSP1_001727
cra1000
cra-1000
gtpl3498
n-ethyl-4-[4-(3-fluorophenyl)-3,6-dihydro-2h-pyridin-1-yl]-6-methyl-n-(2-methylsulfanyl-4-propan-2-ylphenyl)pyrimidin-2-amine
cid 9849313
2-(n-(2-methylthio-4-isopropylphenyl)-n-ethylamino)-4-(4-(3-fluorophenyl)-1,2,3,6-tetrahydropyridin-1-yl)-6-methylpyrimidine
2-pyrimidinamine, n-ethyl-4-(4-(3-fluorophenyl)-3,6-dihydro-1(2h)-pyridinyl)-6-methyl-n-(4-(1-methylethyl)-2-(methylthio)phenyl)-
CHEMBL297986
3899v9a17f ,
unii-3899v9a17f
cra 1000
226948-11-4
SCHEMBL6171730
Q27076916
AKOS040748180

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pretreatment with CRA1000 (20 mg/kg, i.p.) attenuated the incidence of withdrawal signs and naloxone-precipitated increases in noradrenaline turnover."( Involvement of corticotropin-releasing factor receptor subtype 1 in morphine withdrawal regulation of the brain noradrenergic system.
Funada, M; Hara, C; Wada, K, 2001
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1345736Human CRF1 receptor (Corticotropin-releasing factor receptors)1999European journal of pharmacology, Apr-29, Volume: 371, Issue:2-3
In vitro pharmacological profile of nonpeptide CRF1 receptor antagonists, CRA1000 and CRA1001.
AID53814Compound was tested for the inhibition of binding of the radioligand, [125 I-Tyr0]-CRF to rat cerebral cortex membrane2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID176281Minimal effective dose were reported, after oral injection in a CRF-induced anxiety model.2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (23.53)18.2507
2000's12 (70.59)29.6817
2010's1 (5.88)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]